English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Other research materials

Melanotan II

Cyclic melanocortin-receptor research heptapeptide · unapproved for therapeutic or tanning use

Lot-specific · Batch COACAS 121062-08-6RUO
Batch COA
MOQ1 kit (10 vials) per SKU
Supplied formCyclic N-acetylated, C-amidated heptapeptide with an Asp–Lys side-chain lactam bridge
Lead timeConfirmed with quote
Melanotan II — Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA
Melanotan II — Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Research relevance includes melanocortin-receptor pharmacology, cyclic-peptide identity and receptor-selectivity studies
  • Historical human signals must not be presented as approved therapeutic or cosmetic benefits.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
121062-08-6
Formula
C50H69N15O9 for the PubChem free-base structure
Molecular weight
1024.2 g/mol
Appearance
Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA
Purity
Lot-specific released result; request cyclic-form identity, chromatographic purity, quantitative peptide content, counterion/water and residual-solvent data · target, verify batch COA
Storage
Store and handle only under the released-lot COA or manufacturer stability instructions. Keep sealed, dry and protected from light; do not infer solution stability from the lyophilized powder specification.
MOQ
1 kit (10 vials) per SKU
Lead time
Confirmed with quote
PubChem CID 92432

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about Melanotan II

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Early small human studies investigated pigmentation and melanocortin-mediated sexual-function signals, while later literature and regulators documented adverse events and risks associated with unlicensed online products. MT-II is distinct from afamelanotide and from the approved derivative bremelanotide; those approvals do not apply to MT-II or to this lot. The Australian TGA confirmed in May 2026 that no Melanotan II product is entered on the ARTG or approved for Australian supply.

  • Laboratory investigation of melanocortin-receptor pharmacology, cyclic-peptide structure-activity relationships, analytical identity and related research models
  • This is not an approved clinical indication list.

Mechanism context

The question the literature is testing

MT-II is a cyclic alpha-MSH analogue that activates several melanocortin receptors, including MC1R and central MC3R/MC4R pathways. MC1R signaling is linked to melanogenesis, while central melanocortin signaling is linked to appetite and sexual-function observations. Receptor activity depends on the correctly cyclized structure and should be interpreted with the assay system, concentration and reference standard.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context
Routes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Not for human or veterinary use
  • Melanotan II is not an FDA-approved medicine
  • Australia's TGA states that melanotan tanning products are unapproved there, can carry serious risks and may be illegally promoted or supplied; its May 2026 enforcement notice confirms that no Melanotan II product is entered on the ARTG or approved for Australian supply
  • Laboratory users must follow institutional controls and the SDS; chemical purity does not establish sterility, injectable suitability or clinical safety.

Interactions reported in the literature

  • Not established for this Research Use Only reagent
  • No stacking, combination or patient drug-interaction advice is provided.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

Melanotan II batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

  • Blurred preview of a Melanotan II 10 mg batch COA10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

  • Released-lot documentation should identify the exact cyclic sequence and form, theoretical and observed intact mass, LC-MS identity, RP-HPLC purity with method, peptide content, counterion, water and residual solvents
  • Sterility, endotoxin and bioburden require separate specified tests and must not be inferred from HPLC purity.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
MT21010 mg10 vials

Other format

Also available as a nasal spray (US stock)

Black 10 mL nasal spray bottle with a clear cap
10 mL nasal spray bottle

Besides lyophilized vials, Melanotan II is also supplied as a nasal spray solution, shipped from our US stock.

Strengths
10 mg · 20 mg
Bottle sizes
10 mL or 20 mL
Minimum order
10 bottles per strength and bottle size
Ships from
Our US stock

Handling

Plan storage before the parcel arrives

Store and handle only under the released-lot COA or manufacturer stability instructions. Keep sealed, dry and protected from light; do not infer solution stability from the lyophilized powder specification.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Identity: PubChem CID 92432. Human research context: Dorr et al. 1996 (PMID 8637402) and the small 2000 studies (PMIDs 11035391 and 11018622). Quality, safety and regulatory context: the listed peer-reviewed work, the Australian TGA warning published 24 January 2025, its Melanotan II enforcement notice published 21 May 2026, and the UK MHRA's 17 April 2024 official response. Study-specific findings do not authorise human use.
  1. 01

    Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study

    Life Sciences · 1996 · peer-reviewed original research (Phase I clinical study)

    Open source
  2. 02

    Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II

    International Journal of Impotence Research · 2000 · peer-reviewed original research / review of clinical studies

    Open source
  3. 03

    Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction

    Urology · 2000 · peer-reviewed original research (double-blind, placebo-controlled crossover trial)

    Open source
  4. 04

    An unhealthy glow? A review of melanotan use and associated clinical outcomes

    Performance Enhancement & Health · 2014 · systematic literature review

    Open source
  5. 05

    Melanotan-associated melanoma

    British Journal of Dermatology · 2011 · peer-reviewed case report

    Open source
  6. 06

    Evaluation of synthetic alpha-melanocyte-stimulating hormone analogs: an observational study of unregulated, online-available drugs

    Journal of the American Academy of Dermatology · 2022 · peer-reviewed research letter / observational study

    Open source
  7. 07

    The 'Barbie Drug'-marketing and perceptions of melanotan on social media

    Journal of the European Academy of Dermatology and Venereology · 2025 · peer-reviewed research letter (no formal abstract published)

    Open source
  8. 08

    The first preparative solution phase synthesis of melanotan II

    Beilstein Journal of Organic Chemistry · 2008 · peer-reviewed original research (open-access chemistry journal) — included here as a chemistry/manufacturing reference rather than a clinical source

    Open source

Product FAQ

Questions buyers ask about Melanotan II

Which identity details distinguish Melanotan II from related melanocortin peptides?+

Confirm the N-acetylated, C-amidated seven-residue sequence, D-Phe stereochemistry and Asp–Lys side-chain lactam bridge, together with CAS 121062-08-6 for the PubChem free-base record, theoretical mass and supplied salt/counterion. Afamelanotide and bremelanotide are different molecules; their approvals or data cannot qualify an MT-II lot.

Why must the cyclic form be confirmed analytically?+

The side-chain lactam is part of the defined MT-II structure. Confirm the expected free-base intact mass near 1,024.2 Da with high-resolution MS and use peptide mapping, MS/MS or another suitable orthogonal method to verify the modified sequence and bridge. A vendor name or HPLC peak alone cannot exclude linear precursor, deletion products, epimers or an incorrect salt basis.

Evidence before order

Buyer intelligence

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Other research materials

Melanotan I

Afamelanotide reference peptide · approval applies to the SCENESSE controlled-release implant, not this RUO lot

Purity
Lot-specific · Batch COA
CAS
75921-69-6
Lyophilized powderNasal spray available
Hormonal research

PT-141

Bremelanotide · cyclic melanocortin-receptor agonist reference material

Purity
Target ≥ 99.0% · Batch COA
CAS
189691-06-3
Lyophilized powderNasal spray available
Other research materials

Lemon Bottle

Trade-name multi-ingredient material · authenticity, intended external-use versus injection identity and composition must be verified by lot

Purity
Component-specific · Batch COA
CAS
83-88-5
Liquid
Other research materials

Lipo-C (LC216)

Methionine / inositol / choline and B-vitamin multi-component research formulation

Purity
Component-specific · Batch COA
CAS
Confirm per batch COA
Vials